Pages that link to "Q37956110"
Jump to navigation
Jump to search
The following pages link to Targeted therapies: how personal should we go? (Q37956110):
Displaying 50 items.
- Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers (Q26751068) (← links)
- Treatment Individualization in Colorectal Cancer (Q26776215) (← links)
- How many molecular subtypes? Implications of the unique tumor principle in personalized medicine (Q26992045) (← links)
- Somatic mutations in exocrine pancreatic tumors: association with patient survival (Q27852155) (← links)
- New challenges in perioperative management of pancreatic cancer (Q28082422) (← links)
- Lung Cancer Gene Signatures and Clinical Perspectives (Q28387769) (← links)
- Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. (Q33838524) (← links)
- Liquid biopsy: monitoring cancer-genetics in the blood (Q34356149) (← links)
- Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (Q34447986) (← links)
- Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer (Q34485726) (← links)
- Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer (Q34508634) (← links)
- Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas (Q34607312) (← links)
- Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy (Q34911031) (← links)
- Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma (Q35026938) (← links)
- Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer (Q35213124) (← links)
- Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway (Q35897673) (← links)
- Personalized radiotherapy: concepts, biomarkers and trial design (Q36235704) (← links)
- CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer (Q36544662) (← links)
- Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma (Q36763844) (← links)
- Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer (Q37297137) (← links)
- Role of apoptosis in colon cancer biology, therapy, and prevention (Q37331465) (← links)
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer (Q37343279) (← links)
- KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review (Q37369576) (← links)
- Immunological Defects in Neonatal Sepsis and Potential Therapeutic Approaches. (Q37627158) (← links)
- KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation (Q37689595) (← links)
- The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities (Q37987661) (← links)
- Advanced-stage pancreatic cancer: therapy options (Q38102914) (← links)
- Targeting PI3K in Cancer: Any Good News? (Q38105322) (← links)
- Familial rhabdoid tumour 'avant la lettre'--from pathology review to exome sequencing and back again (Q38115209) (← links)
- High-throughput, multiparameter analysis of single cells (Q38167618) (← links)
- Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance (Q38249332) (← links)
- Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium (Q38263008) (← links)
- Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond (Q38368574) (← links)
- Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. (Q38710557) (← links)
- Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma (Q38722567) (← links)
- Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. (Q39098665) (← links)
- Improved Targeting of Cancers with Nanotherapeutics (Q39114835) (← links)
- Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. (Q39356301) (← links)
- Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer (Q42109645) (← links)
- Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation (Q44808305) (← links)
- Which way is forward in the treatment of rectal cancer? (Q46504181) (← links)
- Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. (Q47213006) (← links)
- p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway? (Q48635490) (← links)
- Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer (Q51752412) (← links)
- Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. (Q53612758) (← links)
- Clinical trials for precision oncology using next-generation sequencing. (Q54257611) (← links)
- The BRAF mutation is associated with the prognosis in colorectal cancer. (Q54343834) (← links)
- Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. (Q55113736) (← links)
- Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer (Q57280561) (← links)
- Hurdles in anticancer drug development from a regulatory perspective (Q83473293) (← links)